CANY
IRMD icon

Caxton Associates (New York)’s iRadimed IRMD Stock Holding History

Caxton Associates (New York)’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-8,690
Closed -$244K – 467
2019
Q1 		$244K Hold
8,690
– – 0.04% 302
2018
Q4 		$213K Sell
8,690
-7,758
-47% -$208K 0.03% 237
2018
Q3 		$611K Buy
+16,448
New +$444K 0.04% 203

Other funds holding IRMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
RCMC
RK Capital Management (Colorado) Denver, Colorado $324K AUM 47.52% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
NA
Navellier & Associates Reno, Nevada $960M AUM 79.37% 1-Year Est. Return
CCM
Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Caxton Associates (New York)'s IRMD Position: Q2 2019 in Review

Caxton Associates (New York) sold out of iRadimed (IRMD) in Q2 2019, closing a stake of 8,690 shares — an estimated $244K sold.

Caxton Associates (New York) first reported a position in IRMD in Q3 2018 and held it in 3 quarters. The position peaked at $611K in Q3 2018. 54 funds tracked by Wall St. Rank hold IRMD as of Q2 2019.

  • Caxton Associates (New York) reported no remaining iRadimed position as of Q2 2019 after selling out during the quarter.
  • Caxton Associates (New York) sold 8,690 iRadimed shares in Q2 2019, an estimated $244K.
  • Caxton Associates (New York) first reported a position in iRadimed in Q3 2018 and held it in 3 quarters.
  • Caxton Associates (New York)'s iRadimed position peaked at $611K in Q3 2018.
  • 54 funds tracked by Wall St. Rank held iRadimed as of Q2 2019.

Based on Caxton Associates (New York)'s 13F filing for Q2 2019, filed 14 Aug 2019.